Scroll

nortriptyline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antidepressants, dibenzo[a,d]cycloheptane or cyclopheptene derivatives	1971	72-69-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nortryptyline nortriptyline demethylamitriptylin desitriptilina desmethylamitriptyline noramitriptyline nortriptyline hydrochloride nortriptyline HCl	A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. Molecular weight: 263.38 Formula: C19H21N CLOGP: 4.32 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -5.48 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nortryptyline
nortriptyline
demethylamitriptylin
desitriptilina
desmethylamitriptyline
noramitriptyline
nortriptyline hydrochloride
nortriptyline HCl

A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.

Molecular weight: 263.38
Formula: C19H21N
CLOGP: 4.32
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -5.48
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
75	mg	O
30	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	6.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
t_half (Half-life)	30 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	22 L/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	10 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.12 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Nov. 6, 1964	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Temperature regulation disorder	511.43	13.70	168	30943	5964	63451947
Food allergy	416.64	13.70	170	30941	11231	63446680
Coeliac disease	394.38	13.70	169	30942	12628	63445283
Immunodeficiency	346.22	13.70	178	30933	20076	63437835
Pneumonia aspiration	328.82	13.70	207	30904	34333	63423578
Completed suicide	321.62	13.70	376	30735	145297	63312614
Bursitis	249.24	13.70	179	30932	36862	63421049
Rash erythematous	227.25	13.70	179	30932	42331	63415580
Coma	212.62	13.70	206	30905	64158	63393753
Fluid retention	189.59	13.70	187	30924	59499	63398412

Showing 1 to 10 of 145 entries

Previous1 2 3 4 5…15Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxicity to various agents	326.43	18.08	323	8639	200039	34747930
Sedation	271.11	18.08	124	8838	20882	34927087
Completed suicide	164.00	18.08	161	8801	98007	34849962
Nightmare	160.94	18.08	77	8885	14314	34933655
Nephrolithiasis	124.00	18.08	84	8878	30249	34917720
Product used for unknown indication	94.84	18.08	26	8936	957	34947012
Reversible airways obstruction	91.84	18.08	22	8940	467	34947502
Myokymia	88.35	18.08	16	8946	76	34947893
Suicidal ideation	84.09	18.08	75	8887	40313	34907656
Hyperhidrosis	80.46	18.08	98	8864	75594	34872375

Showing 1 to 10 of 47 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Temperature regulation disorder	507.68	13.35	161	34940	5692	79703595
Completed suicide	471.83	13.35	560	34541	245207	79464080
Food allergy	417.93	13.35	163	34938	10661	79698626
Toxicity to various agents	414.77	13.35	697	34404	420843	79288444
Coeliac disease	399.97	13.35	160	34941	11191	79698096
Immunodeficiency	331.75	13.35	171	34930	21597	79687690
Bursitis	255.02	13.35	172	34929	35672	79673615
Pneumonia aspiration	214.76	13.35	201	34900	66766	79642521
Drug hypersensitivity	196.76	13.35	417	34684	298499	79410788
Hyperhidrosis	189.09	13.35	280	34821	151212	79558075

Showing 1 to 10 of 182 entries

Previous1 2 3 4 5…19Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Trismus	58.08	53.75	16	89	130	89557

Showing 1 to 1 of 1 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N06AA10	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:49103	drug metabolites
CHEBI has role	CHEBI:68495	Type I cell-death inducers
CHEBI has role	CHEBI:176497	geroprotectors
FDA EPC	N0000175752	Tricyclic Antidepressant
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D018759	Adrenergic Uptake Inhibitors

Showing 1 to 10 of 17 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Depressive disorder	indication	35489007
Neuropathic pain	off-label use	247398009
Smoking cessation assistance	off-label use	384742004
Attention deficit hyperactivity disorder	off-label use	406506008
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Sinus tachycardia	contraindication	11092001
Lowered convulsive threshold	contraindication	19260006
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686

Showing 1 to 10 of 27 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.5	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	8.36	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	7.34	WOMBAT-PK	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6.57	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.59	PDSP
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.56	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.51	WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.36	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.07	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.67	CHEMBL

Showing 1 to 10 of 34 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
21B	PDB_CHEM_ID
001502	NDDF
004601	NDDF
1328	INN_ID
13432000	SNOMEDCT_US
203130	RXNORM
2404	IUPHAR_LIGAND_ID
2733	MMSL
2740	MMSL
29666006	SNOMEDCT_US

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0810	CAPSULE	10 mg	ORAL	ANDA	13 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0811	CAPSULE	25 mg	ORAL	ANDA	13 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0812	CAPSULE	50 mg	ORAL	ANDA	13 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-0813	CAPSULE	75 mg	ORAL	ANDA	13 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0678	SOLUTION	10 mg	ORAL	ANDA	19 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0678	SOLUTION	10 mg	ORAL	ANDA	19 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0678	SOLUTION	10 mg	ORAL	ANDA	19 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-567	CAPSULE	10 mg	ORAL	ANDA	18 sections
NORTRIPTYLINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-171	CAPSULE	25 mg	ORAL	ANDA	16 sections
Nortriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	21695-093	CAPSULE	10 mg	ORAL	ANDA	13 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next